Quick Answer
BridgeBio Pharma, Inc. reported Long-Term Debt of $437.34 million for fiscal year 2024.
BridgeBio Pharma, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2024 | $437.34M | -2.0% |
| 2023 | $446.44M | +3.6% |
| 2022 | $430.99M | +0.1% |
| 2021 | $430.75M | +366.1% |
| 2020 | $92.42M | +0.7% |
| 2019 | $91.79M | +68.4% |
| 2018 | $54.51M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $0.00 | -100.0% | — |
| March 31, 2025 | $0.00 | -100.0% | -100.0% |
| December 31, 2024 | $437.34M | -2.0% | +0.3% |
| September 30, 2024 | $436.22M | -1.2% | +0.2% |
| June 30, 2024 | $435.45M | -1.1% | +0.2% |
| March 31, 2024 | $434.72M | -0.2% | -2.6% |
| December 31, 2023 | $446.44M | +3.6% | +1.1% |
| September 30, 2023 | $441.72M | — | +0.3% |
- BridgeBio Pharma, Inc. showed a decrease of -2.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2018–2024 period, BridgeBio Pharma, Inc.’s long-term debt has grown by 702.4% (from $54.51 million to $437.34 million).
- The most recent figure is from BridgeBio Pharma, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 20, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: